Scarica l'app Stockscreener
18.96
4.06%
0.74
Pre-mercato:
19.51
0.55
+2.90%
Precedente Chiudi:
$18.22
Aprire:
$18.09
Volume 24 ore:
1.23M
Relative Volume:
1.37
Capitalizzazione di mercato:
$2.45B
Reddito:
$14.09M
Utile/perdita netta:
$-176.94M
Rapporto P/E:
-8.8186
EPS:
-2.15
Flusso di cassa netto:
$-141.24M
1 W Prestazione:
+3.44%
1M Prestazione:
+0.16%
6M Prestazione:
-26.96%
1 anno Prestazione:
-6.60%
Intervallo 1D:
$18.07
$19.13
Intervallo di 1 settimana:
$17.91
$19.13
Portata 52W:
$14.06
$27.29
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Nome
Newamsterdam Pharma Company Nv
Settore
Industria
Telefono
35 206 2971
Indirizzo
GOOIMEER 2-35, NARRDEN
Confronta NAMS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
18.96 | 2.45B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-10 | Iniziato | Stifel | Buy |
| 2025-06-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-15 | Iniziato | TD Cowen | Buy |
| 2024-03-14 | Iniziato | Scotiabank | Sector Outperform |
| 2024-01-18 | Iniziato | Guggenheim | Buy |
| 2024-01-16 | Iniziato | Piper Sandler | Overweight |
| 2023-10-30 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Newamsterdam Pharma Company Nv Borsa (NAMS) Ultime notizie
NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Citigroup - Defense World
Citi initiates NewAmsterdam Pharma stock with buy rating on cholesterol drug - Investing.com Nigeria
Citi initiates NewAmsterdam Pharma stock with buy rating on cholesterol drug By Investing.com - Investing.com South Africa
Citi Recommends NewAmsterdam Pharma (NAMS) with a Strong Outlook | NAMS Stock News - GuruFocus
How the (NAMS) price action is used to our Advantage - news.stocktradersdaily.com
Stifel initiates NewAmsterdam stock with Buy rating, $44 target By Investing.com - Investing.com Nigeria
NewAmsterdam Pharma’s SWOT analysis: stock poised for cardiovascular breakthrough By Investing.com - Investing.com South Africa
NewAmsterdam Pharma’s SWOT analysis: stock poised for cardiovascular breakthrough - Investing.com
NewAmsterdam Pharma’s (NAMS) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World
NAMS: Needham Reiterates Buy Rating and Maintains Price Target | - GuruFocus
Cantor Fitzgerald maintains NewAmsterdam Pharma stock rating on trial data By Investing.com - Investing.com India
NewAmsterdam Pharma stock maintains buy rating at Stifel on strong data - Investing.com Nigeria
Cantor Fitzgerald maintains NewAmsterdam Pharma stock rating on trial data - Investing.com
California State Teachers Retirement System Raises Position in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
NewAmsterdam Pharma Company N.V. (NAMS) Initiated with a Buy at Stifel - Insider Monkey
Transcript : NewAmsterdam Pharma Company N.V.Special Call - MarketScreener
Frazier Lifesciences Acquisition : NewAmsterdam Pharma R&D Day 2025 - MarketScreener
NewAmsterdam Pharma Schedules R&D Day for June 2025 - TipRanks
Brokers Set Expectations for NAMS FY2026 Earnings - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated by Analysts at Stifel Nicolaus - Defense World
Kalkine: NewAmsterdam Pharma Progress in Nasdaq Index Spotlight Event - Kalkine Media
(NAMSW) Technical Pivots with Risk Controls - news.stocktradersdaily.com
NewAmsterdam Pharma (NAMS): Stifel Initiates Coverage with Buy Rating | NAMS Stock News - GuruFocus
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Analysts Just Trimmed Their Revenue Forecasts By 14% - simplywall.st
Analysts Have Just Cut Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Revenue Estimates By 14% - Yahoo Finance
Stifel Nicolaus Initiates Coverage on NewAmsterdam Pharma With Buy Rating, $44 Price Target - marketscreener.com
Stifel Initiates Coverage on NewAmsterdam Pharma (NAMS) with Pos - GuruFocus
Stifel initiates NewAmsterdam stock with Buy rating, $44 target - Investing.com
NewAmsterdam Pharma (NAMS) Reveals Alzheimer's Biomarker Data fr - GuruFocus
Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib - Benzinga
NewAmsterdam Says Obicetrapib Shows 'Significant' Reduction in Alzheimer's Biomarker; Shares Rise - marketscreener.com
NewAmsterdam reports Alzheimer’s biomarker reduction - Investing.com
NewAmsterdam Pharma (NAMS) Reveals Alzheimer's Biomarker Data from Key Trial | NAMS Stock News - GuruFocus
NewAmsterdam Pharma Reveals Positive Topline Data From BROADWAY Clinical Trial - Nasdaq
NewAmsterdam reports Alzheimer’s biomarker reduction By Investing.com - Investing.com India
NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial - GlobeNewswire
NewAmsterdam Pharma Company N.V. Announces Positive Topline Alzheimer's Disease Data from Br Broadway Clinical Trial - marketscreener.com
Bank of America Corp DE Grows Stock Position in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma Approves Key Proposals at AGM - TipRanks
NewAmsterdam Pharma to Host R&D Day on June 11, 2025 - GlobeNewswire
NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Cantor Fitzgerald - Defense World
NewAmsterdam Pharma R&D Day: Key Pipeline Updates Coming for Revolutionary Cardiovascular Treatments - Stock Titan
NewAmsterdam Pharma (NAMS) versus Its Rivals Head-To-Head Review - Defense World
NewAmsterdam Pharma (NAMS) Receives Overweight Rating from Canto - GuruFocus
Cantor Fitzgerald initiates overweight rating for NewAmsterdam Pharma stock - Investing.com
Cantor Fitzgerald initiates overweight rating for NewAmsterdam Pharma stock By Investing.com - Investing.com India
Cantor Fitzgerald Initiates NewAmsterdam Pharma Overweight With $42 Price Target - marketscreener.com
RBC Capital maintains outperform rating for NewAmsterdam Pharma stock By Investing.com - Investing.com Canada
RBC Capital maintains outperform rating for NewAmsterdam Pharma stock - Investing.com
Newamsterdam Pharma Company Nv Azioni (NAMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Newamsterdam Pharma Company Nv Azioni (NAMS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Topper James N | Director |
Jun 25 '25 |
Buy |
18.26 |
1,260 |
23,012 |
3,026,133 |
| Kling Douglas F | Chief Operating Officer |
Jun 16 '25 |
Option Exercise |
10.20 |
100,000 |
1,019,709 |
144,000 |
| Kling Douglas F | Chief Operating Officer |
Jun 16 '25 |
Sale |
19.29 |
100,000 |
1,929,141 |
44,000 |
| Topper James N | Director |
Jun 16 '25 |
Buy |
19.50 |
8,584 |
167,381 |
3,022,153 |
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):